ArticleScience translational medicine2026

A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma.

Zhongqiu Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.